Search the Newsreel

Revolution Medicines Gains as Investors Continue to Digest Clinical and Regulatory Momentum

Revolution Medicines (RVMD) saw a 3.1% increase, likely due to continued positive investor sentiment surrounding its pancreatic cancer pipeline. This sentiment follows favorable clinical data updates and a new European regulatory step for daraxonrasib in early July, alongside raised analyst price targets. Insiders, however, …

Revolution Medicines’ near-high pause exposes a volume gap after a 21.5% four-week run

RVMD remains in an active weekly Trend Signal and close to its 52-week peak, but the latest pullback came with participation at just 0.5x the 13-week average.

Revolution Medicines Inc (RVMD) carries a 96.2% 12-week surge into July

Momentum measures remain firm in weekly context, though lighter turnover leaves confirmation less complete.

Revolution Medicines Inc (RVMD) extends 12-week biotech surge to 96.2%

The oncology developer’s weekly setup remains firm, with trend and relative-strength readings supportive while volume confirmation is below average.

Revolution Medicines Inc (RVMD) holds active weekly trend after 96.2% 12-week run

The oncology biotech remains on momentum screens, though turnover is not keeping pace with the strength in price.

Revolution Medicines Inc (RVMD) jumps 11.7% as weekly turnover expands

The oncology biotech’s 12-week advance now stands at 83.7%, with Relative Strength high and volume readings supportive but not uniform.

Revolution Medicines Inc (RVMD) adds 5.9% as biotech strength holds in weekly context

The oncology drug developer’s 52-week weekly price path remains firm, though the latest turnover came in below its recent average.

Revolution Medicines’ 60% quarter still commands a premium, but biotech volume is not confirming the move

RVMD added 3.1% in the latest week and remains close to its 52-week high, but participation was below average and Relative Strength has cooled over four weeks.

Why Is Revolution Medicines (RVMD) Up 9.3% Since Last Earnings Report?

RVMD Reports Wider-Than-Expected Loss in Q1, Raises '26 Expense View

Revolution Medicines in the spotlight for earnings post-trial win

Earnings call transcript: Revolution Medicines Q1 2026 focuses on strong cash position

Assessing Revolution Medicines (RVMD) Valuation After Positive RASolute 302 And Zoldonrasib Clinical Updates

Revolution Medicines (RVMD) Is Up 42.9% After Phase 3 Daraxonrasib Survival Data And $750M Equity Raise – Has The Bull Case Changed?

Stocks making the biggest moves premarket: Goldman Sachs, Revolution Medicines, Fastenal & more

Revolution Medicines (RVMD) Soars to All-Time High on Stellar Cancer Treatment Trial

Revolution Medicines (RVMD) Down 8.8% Since Last Earnings Report: Can It Rebound?

Earnings call transcript: Revolution Medicines Q4 2025 reveals strategic growth

Nasdaq, S&P 500 Futures Open The Week On Edge As Earnings, Tariffs, Fed Decision Loom: Why META, NVDA, RVMD, USAR Are On Traders' Radar Today

Stocks making the biggest moves midday: Delta Air Lines, Revolution Medicines, Centene and more